AbbVie Return on Investment 2010-2024 | ABBV

Current and historical return on investment (ROI) values for AbbVie (ABBV) over the last 10 years.
AbbVie ROI - Return on Investment Historical Data
Date TTM Net Income LT Investments & Debt Return on Investment
2024-09-30 $13.82B $64.58B 20.95%
2024-06-30 $12.27B $64.87B 18.38%
2024-03-31 $12.79B $71.85B 18.88%
2023-12-31 $12.76B $62.59B 18.78%
2023-09-30 $15.06B $67.76B 21.11%
2023-06-30 $17.39B $68.71B 23.64%
2023-03-31 $16.17B $72.60B 21.48%
2022-12-31 $18.12B $76.42B 23.50%
2022-09-30 $17.69B $76.43B 22.71%
2022-06-30 $17.39B $75.69B 21.55%
2022-03-31 $18.54B $79.84B 22.21%
2021-12-31 $17.92B $79.63B 20.96%
2021-09-30 $16.60B $87.63B 18.81%
2021-06-30 $15.55B $86.83B 17.14%
2021-03-31 $11.86B $87.92B 12.72%
2020-12-31 $11.36B $90.65B 13.33%
2020-09-30 $11.57B $97.57B 15.17%
2020-06-30 $10.93B $96.79B 18.81%
2020-03-31 $13.58B $55.87B 34.23%
2019-12-31 $12.98B $54.80B 39.95%
2019-09-30 $6.59B $24.90B 25.89%
2019-06-30 $7.13B $23.05B 25.82%
2019-03-31 $6.49B $27.24B 22.66%
2018-12-31 $6.38B $26.56B 20.96%
2018-09-30 $10.61B $33.57B 32.32%
2018-06-30 $10.14B $27.20B 29.31%
2018-03-31 $10.04B $34.46B 26.60%
2017-12-31 $9.55B $36.05B 24.16%
2017-09-30 $10.08B $40.66B 24.72%
2017-06-30 $9.74B $39.83B 23.45%
2017-03-31 $9.47B $41.52B 22.37%
2016-12-31 $9.34B $41.08B 23.07%
2016-09-30 $9.14B $43.75B 23.73%
2016-06-30 $8.66B $42.97B 23.65%
2016-03-31 $8.13B $34.13B 23.88%
2015-12-31 $7.54B $33.19B 26.43%
2015-09-30 $5.01B $36.22B 21.50%
2015-06-30 $4.08B $32.62B 21.47%
2015-03-31 $3.75B $12.06B 23.74%
2014-12-31 $3.41B $12.28B 19.45%
2014-09-30 $5.36B $19.11B 27.97%
2014-06-30 $5.77B $19.69B 30.58%
2014-03-31 $5.71B $19.08B 30.99%
2013-12-31 $5.66B $18.78B 31.39%
2013-09-30 $5.95B $17.95B 33.34%
2013-06-30 $6.18B $17.88B 46.22%
2013-03-31 $6.14B $17.56B 69.13%
2012-12-31 $5.82B $17.99B 129.32%
2012-09-30 $-1.89B -63.22%
2012-06-30 $0.92B 30.83%
2012-03-31 $3.77B 126.18%
2011-12-31 $3.62B $11.96B 121.03%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $294.353B $54.318B
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $692.744B 71.75
Novo Nordisk (NVO) Denmark $460.555B 33.21
Johnson & Johnson (JNJ) United States $368.366B 14.94
Merck (MRK) United States $244.211B 16.23
Novartis AG (NVS) Switzerland $211.084B 14.03
AstraZeneca (AZN) United Kingdom $197.819B 16.83
Pfizer (PFE) United States $142.241B 9.73
Sanofi (SNY) $121.816B 11.03
Innoviva (INVA) United States $1.195B 9.94